This was shown to increase the sensitivity of cancer cells to conventional anti-cancer agents, especially, malignant cells harboring mutant forms of EGFR, which are often dependent on HSP90 for their stability (Lee et al., 2016). This evidence concerns the gene EGFR and cancer.